2012•Journal watchRequires access
Integrase Inhibitor Resistance — On to the Second Generation
Charles B. Hicks
Open publisher page 0 citations
Abstract
The two currently available HIV integrase inhibitors — raltegravir and elvitegravir — share similar resistance profiles, such that resistance to one drug generally confers resistance to the other. However, the investigational, next-generation integrase inhibitor dolutegravir seems to have a distinct resistance profile, retaining significant antiviral activity in patients who have failed raltegravir-based therapy.
In a study supported by the manufacturer of dolutegravir, a …